Literature DB >> 29734298

Patent challenges to antibody and gene-therapy firms on the rise.

Charlotte Harrison.   

Abstract

Mesh:

Substances:

Year:  2018        PMID: 29734298     DOI: 10.1038/nbt0518-382

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN: 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  2 in total

1.  Biotechs recoil at hedge fund manager's patent attacks.

Authors:  Melanie Senior
Journal:  Nat Biotechnol       Date:  2015-07       Impact factor: 54.908

2.  Allergan's Mohawk evergreening patent deal draws criticism, but ultimately may flop.

Authors:  Eva von Schaper
Journal:  Nat Biotechnol       Date:  2017-11-09       Impact factor: 54.908

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.